Horgen ZH/Osaka – Numab Therapeutics will jointly develop and commercialize its multispecific antibody for cancer therapy with the pharmaceutical company Ono Pharmaceutical. Numab will receive an upfront payment and further milestone payments upon exercise of Ono’s option right.